NCT06754501

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical research study is to learn if the combination of atezolizumab and tiragolumab can help to control cancers of unknown primary. The safety and effects of this drug combination will also be studied

Detailed description

Primary Objectives: To assess the anti-tumor activity of tiragolumab and atezolizumab in patients with CUP. Primary Endpoint: confirmed ORR as per RECISTv1.1. Secondary Objectives: To assess the best objective response rate (ORR) (investigator assessed), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS) overall survival (OS) in patients with CUP. Secondary Endpoints: Best overall response rate per RECISTv1.1 (investigator assessed), DCR, DOR, PFS, and OS

Conditions

• Cancer

Interventions

Type	Name	Description
DRUG	Atezolizumab	Given by vein
DRUG	Tiragolumab	Given by vein

Timeline

• Start date: 2025-04-11
• Primary completion: 2027-07-01
• Completion: 2029-07-01
• First posted: 2024-12-31
• Last updated: 2026-02-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study